Novavax Nuvaxovid™ COVID-19 Vaccine Recommended by CHMP for Expanded Conditional Marketing Authorization in the European Union as a Booster for Adults Aged 18 and Older


Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine has been recommended for expanded conditional marketing authorization (CMA) in the European Union (EU) as a homologous and heterologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for adults aged 18 and older. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its opinion on results from two Phase 2 trials, and the UK-sponsored COV-BOOST trial.

This recommendation is a critical step toward being able to offer the first protein-based COVID-19 vaccine registered for use as both a primary series and booster regardless of previous vaccine history in the EU, As COVID-19 continues to evolve, we are committed to increasing global access to diversified vaccine options.”
– Stanley C. Erck, President, and Chief Executive Officer, Novavax.

The CHMP recommendation was based on data from Novavax’ Phase 2 trial conducted in Australia, a separate Phase 2 trial conducted in South Africa, and the UK-sponsored COV-BOOST trial. As part of the Phase 2 trials, a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six months after their primary two-dose vaccination series of Nuvaxovid. The third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials. In the COV-BOOST trial, Nuvaxovid induced a robust antibody response when used as a heterologous third booster dose.

In the Novavax-sponsored trials, following the booster, local and systemic reactions were generally short-lived with a median duration of approximately two days. The incidence of Grade 3 or higher events remained relatively low. Safety reporting of reactogenicity events showed an increasing incidence across all three doses of Nuvaxovid, reflecting the increased immunogenicity seen with a third dose. Medically attended adverse events (AE), potentially immune-mediated medical conditions, and severe AEs occurred infrequently following the booster dose and were balanced between vaccine and placebo groups.

Nuvaxovid has also been approved in Japan, Australia, and New Zealand as a booster in adults aged 18 and older, and is actively under review in other markets.

Next Post

How To Improve Healthcare Supply Chains

It refers to the monitoring and management of the flow of medicines, medical products, and healthcare services from the manufacturer to the patient and helps ensure that healthcare providers and patients get the medications and treatments they need when and where they need them. 1. CLINICIAN ENGAGEMENT Including clinicians in […]